Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 36559 record(s)

Req # A-2023-000432

Correspondence to and from the minister of Mental Health and Addictions concerning possible changes to the guidance on alcohol consumption in the time frame: January 1, 2022 to June 30 and July 1, 2022 to February 28, 2023.

Organization: Health Canada

284 page(s)
February 2024

Req # A-2023-000504

Acknowledgement letters from Health Canada to potential sponsor(s) regarding New Drug Submissions (NDS) currently under review for NURTEC ODT, including proposed indication.

Organization: Health Canada

5 page(s)
February 2024

Req # A-2023-000615

Information related to Tiotropium bromide monohydrate that Health Canada is currently reviewing. The product name and/or Drug Identification Number (DIN) of the reference product for which the Abbreviated New Drug Submission (ANDS) submission for Tiotropium bromide monohydrate medical ingredient was filed.

Organization: Health Canada

1 page(s)
February 2024

Req # A-2023-000738

All documents submitted in the medical device license application, resulting in Rapid Self Test's Medical Device License (MDL) #102099.

Organization: Health Canada

26 page(s)
February 2024

Req # A-2023-000820

With respect to the Abbreviated New Drug Submission (ANDS) for liraglutide accepted into review on August 2017, copies of any Notice of Deficiency (NOD); a Notice of Non-Compliance (NON); a NOD-Withdrawal (NOD-W), a NON-Withdrawal (NON-W) or sponsor’s letter requesting cancellation of their submission, dated after July 2019.

Organization: Health Canada

9 page(s)
February 2024

Req # A-2023-000965

The exact milligram amount of every ingredient in the Natural health products: Zonnic Polar Mint ; Zonnic Berry Frost ; Zonnic Chill Mint ; Zonnic Cranberry Fizz ; Zonnic Tropic Breeze Natural Product Number (NPN): 80125630.

Organization: Health Canada

15 page(s)
February 2024

Req # A-2023-000983

Current standing/ stop sale requests for ELEVAI EXOSOMES distributed by Evolve Medical.

Organization: Health Canada

106 page(s)
February 2024

Req # A-2023-001021

The Section 1.0.7 “Note to the Reviewer” from the generic manufacturer of the Liraglutide Abbreviated New Drug Submission (ANDS) which appears on the Generic Submissions Under Review (GSUR) List.

Organization: Health Canada

16 page(s)
February 2024

Req # A-2023-001028

All correspondence or other records relating to any pre-submission or pre-application meeting(s) requested by a sponsor in respect of a drug submission/application for a product containing the medicinal ingredient semaglutide.

Organization: Health Canada

23 page(s)
February 2024

Req # A-2023-001029

All correspondence in respect of the liraglutide submission which was removed from the Generic Submissions Under Review (GSUR) List some time between March 15, 2022 and December 13, 2022 between Health Canada and the company (sponsor) who submitted the Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

18 page(s)
February 2024
Date modified: